We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > CytRx

News List

CytRx Announces Director Election Results from 2021 Annual Meeting of Stockholders firstwordpharma
July 30, 2021
CytRx Corporation (OTCQB: CYTR) today announced that based on results from its 2021 Annual Meeting of Stockholders (the "Annual Meeting"), both of the Company's Class III director candidates have been elected to the Board of Directors (the "Board").
CytRx Begins Aldoxorubicin Phase 2 Study americanpharmaceuticalreview
May 27, 2020
CytRx highlighted that ImmunityBio and NantKwest announced the initiation of a Phase 2 randomized, two-cohort, open-label study for first and second-line treatment of locally advanced or metastatic pancreatic cancer (QUILT-88).
CytRx Announces Patent Issued for Aldoxorubicin in the Treatment of Brain Cancer americanpharmaceuticalreview
May 10, 2019
CytRx Announces Patent Issued for Aldoxorubicin in the Treatment of Brain Cancer.